Streamlining DrChrono Prior Authorization for Endocrinology

Klivira automates DrChrono prior authorization for endocrinology practices, integrating directly into the EHR to accelerate approvals for high-volume medications and devices.

For revenue cycle directors and prior authorization coordinators at endocrinology practices utilizing DrChrono, managing the increasing volume and complexity of prior authorizations (PAs) for diabetes and metabolic conditions is a significant operational challenge. Klivira provides a purpose-built solution to integrate with DrChrono, streamlining PA workflows and reducing administrative burden.

DrChrono's Role in Endocrinology Workflows

DrChrono, known for its iPad-first design and focus on small ambulatory and concierge practices, offers an intuitive platform for endocrinologists. While DrChrono facilitates clinical documentation, the PA process for high-volume endocrinology treatments often requires manual intervention outside the EHR. Klivira's integration leverages DrChrono's API and FHIR endpoints to bridge this gap, ensuring that clinical data required for PA is seamlessly extracted and submitted.

High-Volume Prior Authorization Categories in Endocrinology

**GLP-1 receptor agonists** (e.g., semaglutide, liraglutide, dulaglutide) and **Dual GIP/GLP-1 agonists** (e.g., tirzepatide) for Type 2 Diabetes and obesity indications.
**SGLT2 inhibitors** (e.g., empagliflozin, dapagliflozin) for T2D, heart failure, and chronic kidney disease indications.
**Continuous Glucose Monitoring (CGM)** systems (e.g., Dexcom G7, FreeStyle Libre 3/2) for diabetes management.
**Insulin pumps and tubeless systems** (e.g., Tandem t:slim X2, Omnipod 5) often paired with CGM for hybrid closed-loop systems.
**Growth hormone therapy** (e.g., somatropin biosimilars) requiring specific diagnostic documentation.

Navigating Documentation Requirements within DrChrono for Endocrinology PA

Endocrinology prior authorizations demand precise clinical documentation, often guided by ADA Standards of Care, AACE Clinical Practice Guidelines, and ATA Guidelines. For GLP-1 RAs, this includes A1c levels, prior medication trials, and specific BMI criteria. CGM and insulin pump PAs require diabetes diagnosis, insulin-requiring status, and patient adherence records. Klivira integrates with DrChrono to pull these critical data points, ensuring that all payer-specific criteria are addressed and submitted accurately, directly from the patient chart.

Common Prior Authorization Denial Reasons in Endocrinology

**GLP-1 obesity-indication coverage gaps** due to restrictive payer policies or lack of coverage for anti-obesity medications.
**Step therapy non-compliance** for GLP-1 RAs in T2D, where payers require trials of metformin or other first-line agents.
**CGM denial for T2D non-insulin-requiring patients**, as most plans reserve coverage for insulin-dependent individuals.
**Biosimilar substitution requirements** for insulin and growth hormone, where formulary preferences are not met.
**Missing or insufficient patient compliance documentation** for ongoing pump or CGM coverage.

Klivira's Integration with DrChrono for Endocrinology Prior Authorization

Klivira directly integrates with DrChrono using its DrChrono API and FHIR endpoints, allowing for automated data extraction from clinical notes and structured fields. This integration powers Klivira’s ADA/AACE-guideline-aware step-therapy logic, GLP-1 indication-specific routing (T2D vs. obesity), and streamlined workflows for CGM and insulin pump re-authorizations. By automating data retrieval and submission, Klivira reduces the manual burden on DrChrono users, minimizing errors and accelerating approval times for critical endocrinology treatments.

Frequently asked questions

How does Klivira handle GLP-1 step therapy requirements for endocrinology patients in DrChrono?

Klivira's platform incorporates ADA/AACE-guideline-aware step-therapy logic. It automatically identifies if prior medication trials, such as metformin, have been documented in DrChrono and ensures this information is included in the PA submission, aligning with payer-specific formulary requirements.

Can Klivira automate CGM re-authorization cycles for DrChrono users?

Yes, Klivira supports periodic CGM re-authorization workflows. Our system integrates with DrChrono to pull necessary adherence documentation and patient data, streamlining the submission process to ensure continuous coverage for patients using devices like Dexcom G7 or FreeStyle Libre 3/2.

What specific data does Klivira pull from DrChrono for endocrinology PAs?

Klivira leverages DrChrono's API and FHIR endpoints to extract key clinical data points. This includes A1c levels, BMI, medication history, diagnostic codes, lab results (e.g., eGFR, IGF-1), and documentation of prior weight-management interventions, all critical for comprehensive PA submissions.

How does Klivira address the variability in obesity medication coverage for DrChrono endocrinology practices?

Klivira's policy engine continuously tracks payer-specific coverage criteria for anti-obesity medications, including GLP-1s like Zepbound or Wegovy. It guides DrChrono users through the specific documentation required for each payer, helping to mitigate denials related to coverage gaps or restrictive BMI criteria.

Is Klivira compatible with DrChrono's mobile-first interface for PA management?

Klivira is designed to integrate seamlessly into existing DrChrono workflows, complementing its mobile-first environment. While the primary PA automation occurs on the backend, the data extraction and submission process is optimized to work efficiently with data captured within DrChrono, regardless of the device used.